Happy Health Raises $75M for AI Smart Ring That Diagnoses Sleep Apnea in Days

Happy Health, a startup founded by physician and stroke survivor Dustin Freckleton, has emerged from stealth after raising $75 million across multiple funding rounds since 2019. The company's core product is an AI-powered smart ring designed to help physicians diagnose sleep apnea — a condition affecting tens of millions of Americans that frequently goes undetected for years. Freckleton's own story is central to the company's origin: he suffered a stroke at 24 during his first year of medical school, was temporarily paralyzed on one side of his body, and wasn't diagnosed with sleep apnea until nearly seven years later. Sleep apnea is linked to elevated stroke risk and conditions like atrial fibrillation, which Freckleton also says he has.

The funding came from ARCH Venture Partners and OpenLoop, both of which have continued backing the company as it cleared key milestones including manufacturing, clinical validation, and FDA clearance for its ring. The most recent funding tranche closed in 2025, and Freckleton says tens of thousands of people have used the platform so far. He declined to share the company's valuation or revenue figures.

What sets Happy Health apart from consumer wearables like the Oura Ring is its end-to-end care model. The ring collects biometric data during sleep and runs it through AI analysis, but the system doesn't stop at tracking. Patients can then consult with physicians in Happy's network who can formally diagnose sleep apnea and prescribe treatments such as CPAP machines or dental devices — all within the same platform. The full package, including the ring, a year of sleep tracking, and physician consultations, costs $396 out of pocket and is often covered by insurance. Freckleton frames the distinction bluntly: rival rings help users understand bad sleep; Happy Health is built to fix it.

Looking ahead, Freckleton envisions expanding the ring's capabilities to monitor other chronic conditions beyond sleep apnea. The company deliberately launched in sleep because the disorder is both underdiagnosed at scale and tightly linked to serious downstream conditions including heart disease and diabetes — making it a high-impact beachhead for a broader health monitoring platform.